Fulgent Genetics to Acquire Bako Diagnostics Assets and StrataDx for $55.5 Million

Fulgent Genetics agrees to buy StrataDx and assets from Bako Diagnostics for $55.5 million. Learn how this cash deal expands ...
MIT Technology Review

Gene resurrection

Thanks to genetic science, gene editing, and techniques like cloning, it’s now possible to move DNA through time, studying ...